Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. METHODS: Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. RESULTS: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs. 46±5% at 2 years, P=0.01) and overall survival (86±4% vs. 75±5% at 2 years, P=0.02 without adjustment for interim analyses). CONCLUSIONS: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898 · cited 2×
“Hypersensitivity reaction 14 (10) 33 (26) 6 (5) 29 (25) 13 (12) 3 (3)”
Self-citationWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Complete response 38 (34) 40 (35) 78 (35) 61±7 86±5”
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Self-citationAdoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Research works printed but not linked: 10
- Schulz G, 1984, Cancer Res, 44, 5914
- Yu AL, 1997, Proc Am Soc Oncol, 6, 1846
- Barker E, 1991, Cancer Res, 51, 144
- Albertini MR, 1997, Clin Cancer Res, 3, 1277
- Hank JA, 1990, Cancer Res, 50, 5234
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Greenwood M, 1926, Rep Public Health Med Subj (Lond), 33, 1
- Barker E, 1993, Cancer Res, 53, 362
- Dallegri F, 1989, Clin Exp Immunol, 77, 58
- Simon T, 2009, Pediatr Blood Cancer, 53, 708
Cited by
Items 501–600 of 1,000
Striking dichotomy in outcome of MYCN‐amplified neuroblastoma in the contemporary era
Kushner, B. H., Modak, S. I., Kramer, K., LaQuaglia, M. P., Yataghene, K., Basu, E. M., Roberts, S. S., & Cheung, N. V. (2014) · Cancer · doi:10.1002/cncr.28687 · Cited by 42
Anderson, C. P., Matthay, K. K., Perentesis, J. P., Neglia, J. P., Bailey, H. H., Villablanca, J. G., Groshen, S. G., Hasenauer, B., Maris, J. M., Seeger, R. C., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25594 · Cited by 38
Self-citationFang, H., Harned, T. M., Kalous, O., Maldonado, V., DeClerck, Y. A., & Reynolds, C. P. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0578 · Cited by 43
“improved the outcome for these patients (4, 5).”
Self-citationLode, H. N., Ehlert, K., Huber, S., Troschke‐Meurer, S., Siebert, N., Zumpe, M., Loibner, H., & Ladenstein, R. L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02457-x · Cited by 39
“A randomized trial has demonstrated that therapy with an anti-GD 2 antibody, interleukin-2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF) and isotretinoin in the maintenance setting improves outcomes of patients with high-risk neuroblastoma (HR-NB) [5].”
BackgroundTargeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology
Kembuan, G. J., Kim, J. Y., Maus, M. V., & Jan, M. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.01.003 · Cited by 39
Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience
Hale, G. A., Arora, M., Ahn, K. W., He, W., Camitta, B. M., Bishop, M. R., Bitan, M., Cairo, M. S., Chan, K. W., Childs, R. W., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.284 · Cited by 39
“Characteristics of patients Did not receive prior auto, N (%) Received prior auto, N (%) Number of patients 97 46 Number of centers 48 24 Age at transplant, median (range), years 5 (<1- 55) 7 (2-32) 0 – 5 51 (53) 9 (20) 6 -10 27 (28) 31 (67) 11 – 20 13 (13) 5 (11) > 20 6 ( 6) 1 ( 2) Male sex 58 (60) 23 (50) Karnofsky…”
InfluentialSelf-citationTargeted Immunotherapy for High-Risk Neuroblastoma—The Role of Monoclonal Antibodies
Parsons, K. W., Bernhardt, M. B., & Strickland, B. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r353 · Cited by 41
LINC00673 rs11655237 C>T confers neuroblastoma susceptibility in Chinese population
Zhang, Z., Chang, Y., Jia, W., Zhang, J., Zhang, R., Zhu, J., Yang, T., Xia, H., Zou, Y., & He, J. (2018) · Bioscience Reports · doi:10.1042/bsr20171667 · Cited by 37
Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma
Hill‐Kayser, C. E., Tochner, Z. A., Li, Y., Kurtz, G. A., Lustig, R. A., James, P., Balamuth, N., Womer, R. B., Mattei, P., Grupp, S. A., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.01.095 · Cited by 37
Self-citationEnhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells
McNerney, K. O., Karageorgos, S. A., Hogarty, M. D., & Bassiri, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00873 · Cited by 37
Ponterio, E., Maria, R. D., & Haas, T. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.565631 · Cited by 40
Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future
Morandi, F., Sabatini, F., Podestà, M., & Airoldi, I. (2021) · Vaccines · doi:10.3390/vaccines9010043 · Cited by 47
“By contrast, IL-2 administration with alternating cycles of GM-CSF in combination with dinutuximab resulted in higher rates of event-free (66% versus 46%) and overall survival after 2 years, compared to standard therapy alone (86% versus 75%) [25,48].”
BackgroundResultMartínez-Sanz, P., van Rees, D. J., van Zogchel, L. M. J., Klein, B. J. A. M., Bouti, P., Olsman, H., Schornagel, K., Kok, I., Sunak, A., Leeuwenburg, K., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002259 · Cited by 37
Raman, S., Buongervino, S. N., Lane, M. V., Zhelev, D. V., Zhu, Z., Cui, H., Martinez, B., Martínez, D., Wang, Y., Upton, K. A., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100344 · Cited by 42
Self-citationMastrangelo, S., Rivetti, S., Triarico, S., Romano, A., Attinà, G., Maurizi, P., & Ruggiero, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312648 · Cited by 38
“who received discontinuous once-daily infusions of dinutuximab on 4 consecutive days [18,50].”
BackgroundDinutuximab: A Review in High-Risk Neuroblastoma
Hoy, S. M. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0420-2 · Cited by 37
“In ANBL0032, the assignment of patients to randomized (1:1) treatment arms (dinutuximab-containing regimen or standard therapy with isotretinoin alone; see Table 1 for treatment regimen details) was stratified by factors thought to potentially affect post-transplantation outcome (e.g. response before ASCT, number of A…”
BackgroundResultInfluentialRaiser, P., Schleiermacher, G., Gambart, M., Dumont, B., Defachelles, A. S., Thébaud, E., Tandonnet, J., Pasqualini, C., Proust, S., Entz‐Werlé, N., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114001 · Cited by 36
Yankelevich, M., Thakur, A. B., Modak, S. I., Chu, R. L., Taub, J. W., Martin, A., Schalk, D. L., Schienschang, A., Whitaker, S. A., Rea, K., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008744 · Cited by 41
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity
Goldberg, J. L., & Sondel, P. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.012 · Cited by 40
Self-citationCheckpoint inhibition in pediatric hematologic malignancies
Davis, K. L., Agarwal, A. M., & Verma, A. R. (2017) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2017.1383542 · Cited by 39
“In neuroblastoma, chimeric antibody therapy targeting GD-2, an associated tumor antigen, has proven to improve outcomes and survival in this disease [8].”
BackgroundFeraco, A. M., Brand, S. R., Gagne, J. J., Sullivan, A. M., Block, S. D., & Wolfe, J. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.26972 · Cited by 37
PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma
Brunen, D., de Vries, R. C., Lieftink, C., Beijersbergen, R. L., & Bernards, R. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0868 · Cited by 39
“org Mol Cancer Ther; 17(4) April 2018 853”
BackgroundInfluentialZoine, J. T., Knight, K. A., Fleischer, L. C., Sutton, K. S., Goldsmith, K. C., Doering, C. B., & Spencer, H. T. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593804 · Cited by 38
“Furthermore, the combination of chemotherapy and a similar monocloncal anti-GD2 antibody in newly diagnosed high-risk NB patients has shown thus far response rates as high as 80%.(23,28,29) Although increased response rates have been achieved, the effect of anti-GD2 antibody and chemotherapy combinations on cure rates…”
BackgroundFactors contributing to variability of glycan microarray binding profiles
Temme, J. S., Campbell, C. T., & Gildersleeve, J. C. (2019) · Faraday Discussions · doi:10.1039/c9fd00021f · Cited by 36
Cavalli, E., Mazzon, E., Mammana, S., Basile, M. S., Lombardo, S. D., Mangano, K., Bramanti, P., Nicoletti, F., Fagone, P., & Petralia, M. C. (2019) · Brain Sciences · doi:10.3390/brainsci9100284 · Cited by 36
“The standard of care (SOC) for NB consists of surgery, chemo-radiotherapy, and more recently, antidisialoganglioside (anti-GD2) immunotherapy [3,4].”
BackgroundBellary, A., Villarreal, A., Eslami, R., Undseth, Q. J., Lec, B., Defnet, A. M., Bagrodia, N., Kandel, J. J., Borden, M. A., Shaikh, S., et al. (2020) · Theranostics · doi:10.7150/thno.45903 · Cited by 37
“High-risk NB is currently treated with maximally intense chemoradiotherapy, immunotherapy, and autologous stem cell transplant [3,4].”
BackgroundImmune characterization of pre-clinical murine models of neuroblastoma
Webb, E. R., Lanati, S., Wareham, C., Easton, A., Dunn, S. N., Inzhelevskaya, T., Sadler, F. M., James, S., Ashton‐Key, M., Cragg, M. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73695-9 · Cited by 37
Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma
Wingerter, A., Malki, K. E., Sandhoff, R., Seidmann, L., Wagner, D., Lehmann, N., Vewinger, N., Frauenknecht, K. B. M., Sommer, C., Traub, F., et al. (2021) · Cancers · doi:10.3390/cancers13030520 · Cited by 36
“Dinutuximab shows activity in combination with chemokines and with temozolomide (TMZ) + irinotecan (IRN) [7,8].”
BackgroundPathania, A. S., Prathipati, P., Olwenyi, O. A., Chava, S. P., Smith, O. V., Gupta, S. C., Chaturvedi, N. K., Byrareddy, S. N., Coulter, D. W., & Challagundla, K. B. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.03.010 · Cited by 41
“Immunotherapy has recently gained traction in high-risk NB treatment and improved survival rates in patients.(22,23) Immunotherapy treatment harnesses the CD8T and natural killer (NK) cells to recognize, target, and eradicate malignant cells.”
BackgroundPascual‐Pasto, G., McIntyre, B. C., Shraim, R., Buongervino, S. N., Erbe, A. K., Zhelev, D. V., Sadirova, S., Giudice, A. M., Martínez, D., Garcia-Gerique, L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004704 · Cited by 37
Self-citationClinical and biological markers of premature aging after autologous SCT in childhood cancer
Vatanen, A., Hou, M., Huang, T., Söder, O., Jahnukainen, T., Kurimo, M., Ojala, T. H., Sarkola, T., Turanlahti, M., Saarinen‐Pihkala, U. M., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.334 · Cited by 41
Engaging plasticity: Differentiation therapy in solid tumors
Bar-Hai, N., & Ishay-Ronen, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944773 · Cited by 35
Sonawane, P., Cho, H. E., Tagde, A., Verlekar, D. U., Yu, A. L.-T., Reynolds, C. P., & Kang, M. H. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12846 · Cited by 39
“18 antibody and cytokines (Yu et al., 2010).”
BackgroundMethodInfluentialSelf-citationExploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs
Becker, D. J., Lin, D., Lee, S. Y., Levy, B. P., Makarov, D. V., Gold, H. T., & Sherman, S. E. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.020339 · Cited by 36
van Wezel, E. M., van Zogchel, L. M. J., van Wijk, J., Timmerman, I., Vo, N.-K., Zappeij‐Kannegieter, L., Decarolis, B., Simon, T., van Noesel, M. M., Molenaar, J. J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00413 · Cited by 39
Anti-glycan monoclonal antibodies: Basic research and clinical applications
Gillmann, K. M., Temme, J. S., Marglous, S., Brown, C. E., & Gildersleeve, J. C. (2023) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2023.102281 · Cited by 39
Singh, A., Ruan, Y., Tippett, T., & Narendran, A. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0222-x · Cited by 36
“Cis-RA has also been found to provide survival advantage in combination with immunotherapy with anti-GD2 antibody, combined with GM-CSF or IL-2 [25].”
BackgroundOlgun, N., Aksoylar, S., Varan, A., Vergin, C. R., Hazar, V., Akıcı, F., Dağdemir, A., Büyükavcı, M., Kebudi, R., Kurucu, N., et al. (2017) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.183205 · Cited by 35
Patel, A. G., Ashenberg, O., Collins, N. B., Segerstolpe, Å., Jiang, S., Slyper, M., Huang, X., Caraccio, C., Jin, H., Sheppard, H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.07.574538 · Cited by 43
Cao, K., Zhang, G., Yang, M., Wang, Y., He, M., Zhang, C., Huang, Y., Lu, J., & Liu, H. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3260 · Cited by 38
Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects
Makimoto, A., Fujisaki, H., Matsumoto, K., Takahashi, Y., Cho, Y., Morikawa, Y., Yuza, Y., Iehara, T., & Tajiri, T. (2024) · Cancers · doi:10.3390/cancers16030544 · Cited by 37
“…of the CCG-3891 trial, the Children’s Oncology Group (COG) in the US declared isotretinoin maintenance therapy as the standard treatment for high-risk neuroblastoma, incorporating it into the standard therapeutic regimens in subsequent American clinical trials for high-risk neuroblastoma [5,49,50].”
BackgroundInfluentialButch, E. R., Mead, P. E., Diaz, V. A., Sheppard, H., Stewart, E. A., Mishra, J. K., Kim, J.-E., Bahrami, A., Dearling, J. L. J., Packard, A. B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3340 · Cited by 34
“18 in patients with high-risk neuroblastoma demonstrated a 20% increase in two-year event-free survival (9).”
BackgroundNervous system: Embryonal tumors: Neuroblastoma
Pudela, C., Balyasny, S., & Applebaum, M. A. (2020) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/70771 · Cited by 34
“Lastly, post-consolidation therapy includes anti–ganglioside 2 (GD2) immunotherapy with cytokines and cis-retinoic acid (Yu et al., 2010).”
BackgroundBatth, I. S., Dao, L. H., Satelli, A., Mitra, A., Yi, S., Noh, H., Li, H., Brownlee, Z., Zhou, S., Bond, J. P., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33140 · Cited by 34
“granulocyte-macrophage colony-stimulating factor or interleukin-2 in a 5-month treatment.(33,34) In another trial using the anti-GD2 ch14.”
MethodTargeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment
Koo, J., Hayashi, M., Verneris, M. R., & Lee‐Sherick, A. B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581107 · Cited by 39
Nguyen, R., Zhang, X., Sun, M., Abbas, S., Seibert, C., Kelly, M. C., Shern, J. F., & Thiele, C. J. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0717 · Cited by 34
Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
Wieczorek, A., Zaniewska-Tekieli, A., Ehlert, K., Pawińska-Wąsikowska, K., Balwierz, W. A., & Lode, H. N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1082771 · Cited by 37
State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?
Amorós-Pérez, B., Rivas-Pardo, B., del Moral, M. G., Subiza, J. L., & Martínez-Naves, E. (2024) · Cells · doi:10.3390/cells13090725 · Cited by 38
“Anti-GD2 monoclonal antibodies have had a great impact in cancer immunotherapy against neuroblastoma [90].”
BackgroundKoehn, T. A., Trimble, L. L., Alderson, K. L., Erbe, A. K., McDowell, K. A., Grzywacz, B. J., Hank, J. A., & Sondel, P. M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00091 · Cited by 35
“More effective treatment strategies are highly sought, including advances via immunotherapeutic options (Yu et al., 2010), currently being further developed in clinical trials.”
BackgroundMethodInfluentialSelf-citationShusterman, S., Naranjo, A. H., Ryn, C. V., Hank, J. A., Parisi, M. T., Shulkin, B. L., Servaes, S. E., London, W. B., Shimada, H., Gan, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0798 · Cited by 35
“18 (dinutuximab) combined with alternating cycles of GM-CSF and IL2 in addition to isotretinoin therapy compared with treatment with isotretinoin alone (8).”
MethodSelf-citationTrial Watch: Adoptive cell transfer for oncological indications
Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046673 · Cited by 35
Optimizing medication adherence in children with cancer
Gupta, S., & Bhatia, S. (2016) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000434 · Cited by 33
“More recently, targeted therapies have been incorporated into treatment protocols, resulting in further advances in survival [3,4].”
BackgroundTreatment of malignant peripheral nerve sheath tumors in pediatric NF1 disease
Martin, E., Flucke, U. E., Coert, J. H., & van Noesel, M. M. (2020) · Child s Nervous System · doi:10.1007/s00381-020-04687-3 · Cited by 33
“The CH(O)14,18 chimeric mousehuman anti-GD2 antibody has proven to be safe and effective in pediatric high risk neuroblastoma tumors resulting in significantly increased OS [106].”
BackgroundDissecting the conformation of glycans and their interactions with proteins
Wang, S., Wu, T., Lee, C., & Yu, J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00684-5 · Cited by 33
Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
Blom, T., Lurvink, R., Aleven, L., Mensink, M. O., Wolfs, T. F. W., Dierselhuis, M. P., van Eijkelenburg, N. K. A., Kraal, K. C. J. M., van Noesel, M. M., van Grotel, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.601076 · Cited by 39
“Pain occurred most frequently during the first immunotherapy course and at lower rates in subsequent courses (2, 8, 9, 16, 18).”
BackgroundResultInfluentialClinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma
Tang, X. X., Shimada, H., & Ikegaki, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650427 · Cited by 35
“Anti-GD2 monoclonal antibodies have improved event-free survival and overall survival in patients with high-risk neuroblastoma (85, 86).”
BackgroundSelf-citationMora, J., Castañeda, A., Gorostegui, M., Santa‐María, V., Garraus, M., Muñoz, J. P., Varo, A., Pérez‐Jaume, S., & Mañé, S. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29121 · Cited by 35
Monoclonal Antibody Therapies for High Risk Neuroblastoma
Furman, W. L. (2021) · Biologics · doi:10.2147/btt.s267278 · Cited by 39
Molecular Basis and Clinical Features of Neuroblastoma
Takita, J. (2021) · JMA Journal · doi:10.31662/jmaj.2021-0077 · Cited by 48
“More recently, it has been reported that monoclonal antibody-based therapies that specifically target disialoganglioside GD2 on neuroblastoma cells have improved response rates for high-risk neuroblastoma ((17)).”
BackgroundInfluentialNeuroblastoma: Emerging trends in pathogenesis, diagnosis, and therapeutic targets
Katta, S. S., Nagati, V., Paturi, A. S. V., Murakonda, S. P., Murakonda, A. B., Pandey, M. K., Gupta, S. C., Pasupulati, A. K., & Challagundla, K. B. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.001 · Cited by 38
Horwacik, I., & Rokita, H. (2015) · APOPTOSIS · doi:10.1007/s10495-015-1103-7 · Cited by 35
Tumor Glycosylation: A Main Player in the Modulation of Immune Responses
Rodríguez, E. (2025) · European Journal of Immunology · doi:10.1002/eji.202451318 · Cited by 37
“It was approved by the FDA for the treatment of high-risk pediatric neuroblastoma, showing improved survival rates in Phase III clinical trials [56, 75].”
Bartolini, A., Paolo, D. D., Noghero, A., Murgia, D., Sementa, A. R., Cilli, M., Pasqualini, R., Arap, W., Bussolino, F., Ponzoni, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0649 · Cited by 32
“CD19 and GD2 membrane antigens (10) are being pursued for targeted radiotherapy and nanoparticle-driven drug delivery (11) as well as for antibody-mediated immunotherapy (12), with some success in the treatment and prevention of neuroblastoma.”
Immunotherapy in pediatric B-cell acute lymphoblastic leukemia
Wyatt, K. D., & Bram, R. J. (2019) · Human Immunology · doi:10.1016/j.humimm.2019.01.011 · Cited by 35
Tong, W., Maira, M., Roychoudhury, R., Galán, A., Brahimi, F., Gilbert, M., Cunningham, A., Josephy‐Hernandez, S. E., Pirvulescu, I., Moffett, S., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.03.018 · Cited by 32
Dubot, P., Astudillo, L. M., Therville, N., Sabourdy, F., Stirnemann, J., Levade, T., & Andrieu‐Abadie, N. (2020) · Cancers · doi:10.3390/cancers12020475 · Cited by 33
“, nti-GD2) have shown improved outcomes in pa ients with solid cancers su h as n uroblastoma [9].”
BackgroundWei, S., Nguyen, T. H., Yang, I., Mook, D. G., Makena, M. R., Verlekar, D. U., Hindle, A., Martinez, G. M., Yang, S., Shimada, H., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2563-4 · Cited by 34
Self-citationBerlanga, P., Pasqualini, C., Pötschger, U., Sangüesa, C., Castellani, M. R., Cañete, A., Luksch, R., Elliot, M., Schreier, G., Kropf, M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.020 · Cited by 32
Granger, M. P., Naranjo, A. H., Bagatell, R., DuBois, S. G., McCune, J. S., Tenney, S. C., Weiss, B., Mossé, Y. P., Asgharzadeh, S., Grupp, S. A., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.03.006 · Cited by 37
Self-citationMartínez-Sanz, P., Hoogendijk, A. J., Verkuijlen, P., Schornagel, K., van Bruggen, R., van den Berg, T. K., Tytgat, G. A. M., Franke, K., Kuijpers, T. W., & Matlung, H. L. (2021) · Cancers · doi:10.3390/cancers13174261 · Cited by 32
“In neuroblastoma, the standard of care for high-risk patients involves antibody therapy with the anti-disialoganglioside (GD2) antibody dinutuximab, which has greatly increased the survival of patients since its implementation in the treatment protocol [14,15].”
BackgroundEvers, M., Stip, M. C., Keller, K. M., Willemen, H. L. D. M., Nederend, M., Jansen, M., Chan, C., Budding, K., Nierkens, S., Valerius, T., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003163 · Cited by 32
Modak, S. I., Kushner, B. H., Kramer, K., Vickers, A. J., Cheung, I. Y., & Cheung, N. V. (2013) · OncoImmunology · doi:10.4161/onci.23402 · Cited by 32
Androgen-Regulated Transcriptional Control of Sialyltransferases in Prostate Cancer Cells
Hatano, K., Miyamoto, Y., Mori, M., Nimura, K., Nakai, Y., Nonomura, N., & Kaneda, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031234 · Cited by 34
Ten Challenges in the Management of Neuroblastoma
Gains, J. E., Mandeville, H., Cork, N., Brock, P. R., & Gaze, M. N. (2012) · Future Oncology · doi:10.2217/fon.12.70 · Cited by 34
Ladenstein, R. L., Pötschger, U., Siabalis, D., Garaventa, A., Bergeron, C., Lewis, I. J., Stein, J., Kohler, J., Shaw, P. J., Holter, W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5465 · Cited by 32
Huibregtse, K. E., Vo, K. T., DuBois, S. G., Fetzko, S., Neuhaus, J. M., Batra, V., Maris, J. M., Weiss, B., Marachelian, A., Yanik, G. A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.017 · Cited by 33
“Despite these intensive measures that have improved event-free survival (EFS), outcomes remain unsatisfactory for children with high-risk disease [1,3,4].”
BackgroundSelf-citationAACR Cancer Progress Report 2012
Cantley, L. C., Dalton, W. S., DuBois, R. N., Finn, O. J., Futreal, P. A., Golub, T. R., Hait, W. N., Lozano, G., Maris, J. M., Nelson, W. G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2891 · Cited by 36
“18, in combination with two factors that also boost the killing power of the immune system, has been shown in clinical trials to increase dramatically—by 20 percentage points—the chance that a child with high-risk neuroblastoma will be cancer free two years later (109).”
BackgroundSelf-citationAdvances in chimeric antigen receptor immunotherapy for neuroblastoma.
Heczey, A. A., & Louis, C. U. (2013) · PubMed · Cited by 34
Towards a turning point of neuroblastoma therapy
Tonini, G. P., Nakagawara, A., & Berthold, F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.017 · Cited by 33
Clinical Presentation, Evaluation, and Management of Neuroblastoma
Sharma, R., Mer, J., Lion, A., & Vik, T. A. (2018) · Pediatrics in Review · doi:10.1542/pir.2017-0087 · Cited by 32
Tibbetts, R., Yeo, K. K., Muthugounder, S., Lee, M.-H., Jung, C., Porras-Corredor, T., Sheard, M. A., & Asgharzadeh, S. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02963-y · Cited by 31
“The addition of anti-GD2 antibody (dinutuximab) to post-consolidation therapy of high-risk NBL improved 2-year event-free survival when compared to patients treated with isotretinoin alone [4].”
ResultThe role of glycosylation in clinical allergy and immunology
Hale, R. C., Morais, D., Chou, J. S., & Stowell, S. R. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.09.003 · Cited by 31
Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression
Shaw, T. I., Wagner, J., Tian, L., Wickman, E., Poudel, S., Wang, J., Paul, R., Koo, S. C., Lu, M., Sheppard, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47649-y · Cited by 35
“For example, antibodies against the fetal antigen GD2, which is expressed by neuroblastoma, are now routinely used in the treatment of high-risk neuroblastoma, and GD2-CAR T cells have also shown promising results in early phase clinical studies 49,50 .”
New aspects of neuroblastoma treatment: ASPHO 2011 symposium review
Zage, P. E., Louis, C. U., & Cohn, S. L. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24116 · Cited by 34
“86%, respectively) [33], leading to closure of the study arm with maintenance therapy alone and continued studies to better assess the side effect profile of ch14.”
BackgroundSelf-citationJiao, P., Zhou, H., Otto, M., Mu, Q., Li, L., Su, G., Zhang, Y., Butch, E. R., Snyder, S. E., Jiang, G., et al. (2011) · Journal of the American Chemical Society · doi:10.1021/ja206118a · Cited by 31
Targeted therapies for advanced Ewing sarcoma family of tumors
Jiang, Y., Ludwig, J. A., & Jankú, F. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.008 · Cited by 33
Berbegall, A. P., Villamón, E., Tadeo, I., Martinsson, T., Cañete, A., Castel, V., Navarro, S., & Noguera, R. (2014) · Neoplasia · doi:10.1016/j.neo.2014.05.012 · Cited by 32
“Moreover, multiple ongoing immunotherapeutic approaches have been successfully applied in childhood and older relapsed or refractory stage 4 NB [20–24].”
Background64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET Radiotracer Targeting Neuroblastoma and Melanoma
Vāvere, A. L., Butch, E. R., Dearling, J. L. J., Packard, A. B., Navid, F., Shulkin, B. L., Barfield, R. C., & Snyder, S. E. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.104208 · Cited by 32
“Although all neuroblastoma tumors show some level of GD2 expression, a significant fraction of patients do not respond to therapy (20).”
BackgroundTsai, Y.-C. (2013) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000215 · Cited by 31
“However, tumor associated GD2 has recently been shown to be effective target for immunotherapy [6].”
BackgroundNolan, J., Salvucci, M., Carberry, S., Barat, A., Segura, M. F., Fenn, J., Prehn, J. H. M., Stallings, R. L., & Piskareva, O. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.559553 · Cited by 32
“Despite improvements in patient survival with recently developed immunotherapies, a substantial proportion of neuroblastoma patients either do not respond to treatment or relapse with the acquisition of drug resistance and an overall survival probability of 20% (Yu et al., 2010; Gatta et al., 2014; Berlanga et al., 20…”
BackgroundNguyen, R., Houston, J., Chan, W. K., Finkelstein, D., & Dyer, M. A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2108-6 · Cited by 32
“These studies were performed with proliferating neuroblastoma cells and differentiated neuroblastoma cells that were treated with all-trans retinoic acid (ATRA), which is used with anti-GD2 antibody therapy in the clinic [6].”
InfluentialWhole tumor cell vaccines engineered to secrete GM‐CSF (GVAX)
Soiffer, R. J., Kooshesh, K. A., & Ho, V. T. (2021) · ImmunoMedicine · doi:10.1002/imed.1025 · Cited by 32
Olgun, N., Çeçen, E., İnce, D., Kızmazoğlu, D. Ç., Baysal, B., Önal, A., Özdoğan, Ö., Güleryüz, H., Çetingöz, R., Demiral, A. N., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1041443 · Cited by 31
“Alberto Garaventa, Giannina Gaslini Institute (IRCCS), Italy Mehmet Fevzi Ozkaynak, New York Medical College, United States *CORRESPONDENCE Nur Olgun nur.olgun@deu.edu.tr”
BackgroundPre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma
Sabnis, N. A., Pratap, S., Akopova, I., Bowman, P., & Lacko, A. G. (2013) · Frontiers in Pediatrics · doi:10.3389/fped.2013.00006 · Cited by 30
Furman, W. L., McGregor, L. M., McCarville, M. B., Onciu, M. M., Davidoff, A. M., Kovach, S., Hawkins, D., McPherson, V. J., Houghton, P. J., Billups, C. A., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9724-3 · Cited by 32
“6%), similar to that in a recently published COG study [52].”
Loi, M., Becherini, P., Emionite, L., Giacomini, A., Cossu, I., Destefanis, E., Brignole, C., Paolo, D. D., Piaggio, F., Perri, P., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.009 · Cited by 30
Shusterman, S., Grant, F. D., Lorenzen, W. A., Davis, R. T., Laffin, S., Drubach, L. A., Fahey, F. H., & Treves, S. T. (2011) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2011.06.001 · Cited by 30
Ruf, P., Schäfer, B., Eißler, N., Mocikat, R., Heß, J., Plöscher, M., Wosch, S., Suckstorff, I., Zehetmeier, C., & Lindhofer, H. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-219 · Cited by 31
“18 in combination with IL-2 and GM-CSF demonstrated improved overall survival in high risk NB patients as compared to standard therapy (isotretionin) alone [9].”
BackgroundSubsequent Malignant Neoplasms in Pediatric Patients Initially Diagnosed With Neuroblastoma
Federico, S. M., Allewelt, H. B., Spunt, S. L., Hudson, M. M., Wu, J., Billups, C. A., Jenkins, J., Santana, V. M., Furman, W. L., & McGregor, L. M. (2014) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000148 · Cited by 30
Yu, A. L.-T., Hung, J., Ho, M., & Yu, J. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0138 · Cited by 31
“Analysis of the 226 randomized patients showed that 2-year EFS (66% – 5% vs. 46% – 5%, P = 0.01) and OS (86% – 4% vs. 75% – 5%, P = 0.02) were signifi-cantly higher for patients randomized to immunotherapy [43].”
InfluentialSelf-citation
Metadata
- Authors
- Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., Shimada, H., Grupp, S. A., Seeger, R., Reynolds, C. P., Buxton, A., Reisfeld, R. A., Gillies, S. D., Cohn, S. L., Maris, J. M., & Sondel, P. M.
- Affiliations
- University of California San Diego (US)
- Levine Children's Hospital (US)
- Boston Children's Hospital (US)
- Duke Medical Center (US)
- National Institutes of Health (US)
- University of Southern California (US)
- University of California, San Francisco (US)
- Children's Hospital of Philadelphia (US)
- Texas Tech University (US)
- Children's Oncology Group (US)
- Scripps Research Institute (US)
- University of Chicago (US)
- University of Wisconsin–Madison (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-30
- Volume
- 363
- Issue
- 14
- Pages
- 1324-1334
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3086629
- OpenAlex
- W2130465135
- Cited by
- 1,835
- References
- 38
- Citations by year
- 2026: 99 · 2025: 98 · 2024: 124 · 2023: 133 · 2022: 142 · 2021: 151 · 2020: 156 · 2019: 107 · 2018: 107 · 2017: 139 · 2016: 105 · 2015: 115 · 2014: 95 · 2013: 103 · 2012: 92
- FWCI
- 49.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CA98543)
- U.S. Food and Drug Administration (FD-R-002319)
- National Cancer Institute (CA‐98413, U10 CA-98413, U10-CA98543, U10CA098413, R01CA032685, U10CA29139, U10CA029139, U10CA098543, CA-98543)
- Topics
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- neuroblastoma, GD2, GM-CSF, interleukin-2, isotretinoin, immunotherapy, high-risk neuroblastoma, event-free survival, overall survival, disialoganglioside, stem cell transplantation, multimodal therapy
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Child, Child, Preschool, Combined Modality Therapy, Drug Therapy, Combination, Gangliosides, Humans, Immunotherapy, Infant, Interleukin-2, Neuroblastoma, Isotretinoin, Survival Analysis, Granulocyte-Macrophage Colony-Stimulating Factor, Stem Cell Transplantation, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.